ERYAPORO

This brand name is authorized in Nigeria.

Active ingredients

The drug ERYAPORO contains one active pharmaceutical ingredient (API):

1	Erythromycin UNII LXW024X05M - ERYTHROMYCIN STEARATE
	Erythromycin exerts its antimicrobial action by binding to the 50S ribosomal sub-unit of susceptible microorganisms and suppresses protein synthesis. Erythromycin is bacteriostatic and bactericidal depending on its concentration and the type of organism.
	Read more about Erythromycin

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
C4-0351	Tablet	Eryaporo Tablets TAB 500 mg	Erythromycin Stearate 500 mg	20/12/2019
C4-0419	Powder for suspension	ERYAPORO 125 POWDER FOR ORAL SUSPENSION PWD_F_SOL 125 mg/5 mL 1 X1OOML	ERYAPORO 125 POWDER FORORAL SUSPENSION ERYAPORO 125 ERYTHROMYCIN ETHYLSUCCINATE USP 125MG/5ML POM POWDER FOR ORAL SUSPENSION 1 X1OOML ANTIBIOTIC PRIYA PHARMACEUTICAL LIMITED NO. C1, AIRPORT ROAD, 2F, KANO, STATE FREDUN PHARMACEUTICALS LIMITED 14, 15, 16, ZORABIAN INDUSTRIAL COMPLEX, VEOOR, PALGHAR- 401404, INDIA GMP-RBC; LR- SATIS; FEES- PAID; NP: NA 16/01/2019 R R R C4-0419	30/01/2020

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J01FA01	Erythromycin	J Antiinfectives for systemic use → J01 Antibacterials for systemic use → J01F Macrolides, lincosamides and streptogramins → J01FA Macrolides
Discover more medicines within J01FA01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	C4-0351, C4-0419